Esophageal cancer occurs in the cells that line the inside of the esophagus. Major symptoms include difficulty in swallowing (dysphagia), unintentional weight loss, chest pain, worsening indigestion or heartburn, coughing or hoarseness. Drugs approved by the Food and Drug Administration (FDA) such as Docetaxel, Trifluridine, and Tipiracil Hydrochloride are extensively used chemotherapy for treatment of esophageal cancer. Immunotherapy drug named Pembrolizumab is also used for the treatment of esophageal cancer. In 2017, FDA granted accelerated approval to pembrolizumab (Keytruda) for patients suffering from recurrent locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma.
Market Dynamics
Increasing prevalence of esophageal cancer worldwide is expected to boost esophageal cancer drugs market growth. According to World Cancer Research Fund (WCRF) International 2018, esophageal cancer is the seventh most commonly occurring cancer in men and the 13th most commonly occurring cancer in women. There were over 500,000 new cases in 2018, globally. Moreover, geriatric population is at high risk of developing esophageal cancer and men are more vulnerable to developing esophageal cancer. For instance, according to a data published in American Society of Clinical Oncology (ASCO) in 2018, it is estimated that people between the ages of 45 and 70 have the highest risk of esophageal cancer.
However, no drug therapy has been used to cure esophageal cancer completely and the survival rates of esophageal cancer patient significantly decreases after 5 years of treatment. The esophageal cancer drugs do not have any reliability after 5 years of treatment, which is expected to hamper growth of the esophageal cancer drugs market. For instance, according to the study published in the ASCO in January 2019, the 5-year survival rate of people with esophageal cancer is 19%.
Key features of the study:
- This report provides in-depth analysis of the esophageal cancer drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2019 – 2027, considering 2018 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global esophageal cancer drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Genentech, Inc., Sanofi-Aventis, and Merck & Co.
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global esophageal cancer drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
- Global Esophageal Cancer Drugs Market, By Therapy Type:
- Chemotherapy
- Docetaxel
- Irinotecan
- Trifluridine and Tipiracil
- Carboplatin and Paclitaxel
- Cisplatin and 5-fluorouracil
- Cisplatin with Capecitabine
- Targeted Drug Therapy
- Immunotherapy
- Global Esophageal Cancer Drugs Market, By Disease Indication:
- Adenocarcinomas
- Gastrointestinal Stromal Tumors
- Carcinoid Tumors
- Squamous Cell Carcinoma
- Others
- Global Esophageal Cancer Drugs Market, By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Global Esophageal Cancer Drugs Market, By Region:
- North America
- By Country:
- By Therapy Type:
- Chemotherapy
- Docetaxel
- Irinotecan
- Trifluridine and Tipiracil
- Carboplatin and Paclitaxel
- Cisplatin and 5-fluorouracil
- Cisplatin with Capecitabine
- Targeted Drug Therapy
- Immunotherapy
- By Disease Indication:
- Adenocarcinomas
- Gastrointestinal Stromal Tumors
- Carcinoid Tumors
- Squamous Cell Carcinoma
- Others
- By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Therapy Type:
- Chemotherapy
- Docetaxel
- Irinotecan
- Trifluridine and Tipiracil
- Carboplatin and Paclitaxel
- Cisplatin and 5-fluorouracil
- Cisplatin with Capecitabine
- Targeted Drug Therapy
- Immunotherapy
- By Disease Indication:
- Adenocarcinomas
- Gastrointestinal Stromal Tumors
- Carcinoid Tumors
- Squamous Cell Carcinoma
- Others
- By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Therapy Type:
- Chemotherapy
- Docetaxel
- Irinotecan
- Trifluridine and Tipiracil
- Carboplatin and Paclitaxel
- Cisplatin and 5-fluorouracil
- Cisplatin with Capecitabine
- Targeted Drug Therapy
- Immunotherapy
- By Disease Indication:
- Adenocarcinomas
- Gastrointestinal Stromal Tumors
- Carcinoid Tumors
- Squamous Cell Carcinoma
- Others
- By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Therapy Type:
- Chemotherapy
- Docetaxel
- Irinotecan
- Trifluridine and Tipiracil
- Carboplatin and Paclitaxel
- Cisplatin and 5-fluorouracil
- Cisplatin with Capecitabine
- Targeted Drug Therapy
- Immunotherapy
- By Disease Indication:
- Adenocarcinomas
- Gastrointestinal Stromal Tumors
- Carcinoid Tumors
- Squamous Cell Carcinoma
- Others
- By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Therapy Type:
- Chemotherapy
- Docetaxel
- Irinotecan
- Trifluridine and Tipiracil
- Carboplatin and Paclitaxel
- Cisplatin and 5-fluorouracil
- Cisplatin with Capecitabine
- Targeted Drug Therapy
- Immunotherapy
- By Disease Indication:
- Adenocarcinomas
- Gastrointestinal Stromal Tumors
- Carcinoid Tumors
- Squamous Cell Carcinoma
- Others
- By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Therapy Type:
- Chemotherapy
- Docetaxel
- Irinotecan
- Trifluridine and Tipiracil
- Carboplatin and Paclitaxel
- Cisplatin and 5-fluorouracil
- Cisplatin with Capecitabine
- Targeted Drug Therapy
- Immunotherapy
- By Disease Indication:
- Adenocarcinomas
- Gastrointestinal Stromal Tumors
- Carcinoid Tumors
- Squamous Cell Carcinoma
- Others
- By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Company Profiles
- Amgen Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Eli Lilly and Company
- Hoffmann-La Roche
- Bristol-Myers Squibb Company
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb
- GlaxoSmithKline Plc.
- Novartis AG
- Johnson & Johnson
- Gilead Sciences
- Genentech Inc.
- Sanofi-Aventis
- Merck & Co.
“*” marked represents similar segmentation in other categories in the respective section.
